X4 Pharmaceuticals (XFOR) Cash from Operations (2017 - 2025)
X4 Pharmaceuticals' (XFOR) quarterly Cash from Operations came in at 15518000.0 in Q4 2025, up 52.97% YoY from 10144563.52 in Q4 2024, and up 44.18% on a QoQ basis from 27800000.0 in Q3 2025.
X4 Pharmaceuticals (XFOR) Cash from Operations (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 9 years of Cash from Operations data on file, last reported at 15518000.0 in Q4 2025.
- Quarterly Cash from Operations rose 52.97% year-over-year to 15518000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 85618000.0 (up 47.96% YoY) and the FY2025 annual result came in at 85618000.0, up 34.59% from the prior year.
- Cash from Operations advanced to 15518000.0 in Q4 2025, from 27800000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 12368000.0 in Q1 2025 to a low of 68800000.0 in Q3 2023.
- A 5-year average of 28455400.0 and a median of 23370500.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations sank 256.37% — and 2025, when it jumped 63.19%.
- Tracing XFOR's Cash from Operations over 5 years: stood at 19053000.0 in 2021, then slipped by 0.21% to 19093000.0 in 2022, then sank by 45.33% to 27747000.0 in 2023, then decreased by 18.91% to 32995000.0 in 2024, then surged by 52.97% to 15518000.0 in 2025.
- The last three Cash from Operations figures came in at 15518000.0 (Q4 2025), 27800000.0 (Q3 2025), and 29932000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.52 Mn |
| Dec 31, 2025 | -15.52 Mn |
| Sep 30, 2025 | -27.80 Mn |
| Sep 30, 2025 | -27.80 Mn |
| Jun 30, 2025 | -29.93 Mn |
| Jun 30, 2025 | -29.93 Mn |
| Mar 31, 2025 | -12.37 Mn |
| Mar 31, 2025 | -12.37 Mn |
| Dec 31, 2024 | -33.00 Mn |
| Dec 31, 2024 | -33.00 Mn |
| Sep 30, 2024 | -34.03 Mn |
| Sep 30, 2024 | -34.03 Mn |
| Jun 30, 2024 | -63.90 Mn |
| Jun 30, 2024 | -63.90 Mn |
| Mar 31, 2024 | -33.60 Mn |
| Mar 31, 2024 | -33.60 Mn |
| Dec 31, 2023 | -27.75 Mn |
| Dec 31, 2023 | -27.75 Mn |
| Sep 30, 2023 | -68.80 Mn |
| Sep 30, 2023 | -68.80 Mn |